Skip to main content
Erschienen in: Cancer & Metabolism 1/2014

Open Access 01.05.2014 | Poster presentation

The biochemical mechanism of hypoxia-induced mobilization of glycogen in cultured cancer cell

verfasst von: Mung Kwan Long, Wong Nai Sum

Erschienen in: Cancer & Metabolism | Sonderheft 1/2014

download
DOWNLOAD
print
DRUCKEN
insite
SUCHEN

Background

Metabolic reprogramming is one of the strategies adopted by cancer cells to survive hypoxic conditions. Recent findings suggest that hypoxic cancer cells derive the energy that they need through glycolysis using glucose mobilized from intracellular glycogen reserve. Glycogen phosphorylase (GP) is the major rate-determining enzyme for glycogen mobilization in many normal cells under the condition of starvation or physical exercise. The lysosomal alpha-glucosidase (GAA) has also been implicated in glycogen mobilization since deficiency of this enzyme is known to result in Glycogen Storage Disease Type II (Pompe disease). Although a role for GP in the mobilization of glycogen by cancer cells depleted of oxygen had been demonstrated, whether a similar role for GP (and GAA) could be demonstrated under deprivation of both glucose and oxygen is not yet known. This issue is addressed in this study by examining the intracellular level of glycogen in the absence and presence of pharmacological inhibitors of GP and/or GAA.

Materials and methods

The Hela, HEK293 and HT29 cancer cell lines were subjected to hypoxic conditions (1%O2) in the presence or absence of glucose for 3 hours. The effect of these hypoxic conditions on intracellular glycogen level was examined in the presence and absence of inhibitors for glycogen phosphorylase [CAS 648926-15-2] or lysosomal alpha glucosidase (castanospermine or miglitol).

Results

We showed that steady-state intracellular glycogen is significantly lowered (>50%) only when cultured cancer cell (Hela, HEK293 and HT29) were deprived of both glucose and oxygen for 3 hours. The hypoxia-induced lowering of intracellular glycogen was alleviated by the presence of glycogen phosphorylase inhibitor (CAS 648926-15-2) but not alpha glucosidase inhibitor (castanospermine or miglitol). The simultaneous presence of inhibitors for both enzymes did not have a synergistic effect in preventing hypoxia-induced glycogen mobilization as compared to that observed for (CAS 648926-15-2) alone. Hypoxia had no significant effect on both in vitro glycogen phosphorylase activity and mRNA level of glycogen phosphorylase. The total abundance of glycogen synthase and its phosphorylated form remained unchanged upon hypoxic treatment, suggesting that down-regulation of glycogen synthesis is unlikely to contribute to glycogen depletion. Addition of cycloheximide and actinomycin D had no effect on hypoxia-induced mobilization of glycogen, suggesting that de novo protein synthesis and mRNA synthesis are not required for hypoxia-induced glycogen consumption. These data suggest that glycogen phosphorylase plays a dominant role in glycogen utilization under hypoxic conditions in the absence of extracellular glucose.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://​creativecommons.​org/​licenses/​by/​4.​0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://​creativecommons.​org/​publicdomain/​zero/​1.​0/​) applies to the data made available in this article, unless otherwise stated.
download
DOWNLOAD
print
DRUCKEN
Metadaten
Titel
The biochemical mechanism of hypoxia-induced mobilization of glycogen in cultured cancer cell
verfasst von
Mung Kwan Long
Wong Nai Sum
Publikationsdatum
01.05.2014
Verlag
BioMed Central
Erschienen in
Cancer & Metabolism / Ausgabe Sonderheft 1/2014
Elektronische ISSN: 2049-3002
DOI
https://doi.org/10.1186/2049-3002-2-S1-P37

Weitere Artikel der Sonderheft 1/2014

Cancer & Metabolism 1/2014 Zur Ausgabe

Bei seelischem Stress sind Checkpoint-Hemmer weniger wirksam

03.06.2024 NSCLC Nachrichten

Wie stark Menschen mit fortgeschrittenem NSCLC von einer Therapie mit Immun-Checkpoint-Hemmern profitieren, hängt offenbar auch davon ab, wie sehr die Diagnose ihre psychische Verfassung erschüttert

Antikörper mobilisiert Neutrophile gegen Krebs

03.06.2024 Onkologische Immuntherapie Nachrichten

Ein bispezifischer Antikörper formiert gezielt eine Armee neutrophiler Granulozyten gegen Krebszellen. An den Antikörper gekoppeltes TNF-alpha soll die Zellen zudem tief in solide Tumoren hineinführen.

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

15% bedauern gewählte Blasenkrebs-Therapie

29.05.2024 Urothelkarzinom Nachrichten

Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.